Introduction Plantain, a herbal remedy, has been reported to interfere with therapeutic drug monitoring of digoxin. We evaluated three commercially available plantain products for potential interference with therapeutic drug monitoring of digoxin and 13 other common drugs.
Introduction
Plantain (Plantago major), a green, weedy plant native to Europe and Asia, now grows everywhere in the world and its leaf is used as a herbal remedy to treat bronchitis, cough, peptic ulcer and urinary tract infection. It is also indicated for topical application for insect bites and dermatitis. Plantain should not be confused with the banana-like vegetable of the same name. Slifman et al. 1 reported two cases where one patient showed a serum digoxin level of 3.66 ng/mL and another patient showed a digoxin level of 0.9 ng/mL. In this case, the cause of falsely elevated digoxin measure-ments was found to be contamination of plantain with Digitalis lantana. 1 Miller 2 reported that plantain may interfere with therapeutic drug monitoring of digoxin. More recently, Cole and Fetrow 3 commented on contamination of plantain with D. lantana. However, there is no report of any study that investigated potential interference of plantain with monitoring of any other common drugs, except digoxin. As plantain is used by the general population and this product is freely available without prescription in any health food store, we studied potential interference of plantain with therapeutic drug monitoring of digoxin and 13 other commonly monitored drugs.
Materials and methods
Plantain capsules comprising dry plantain leaves (395 mg dry powder per capsule) manufactured by Nature's Way Products Inc. (Springville, Utah) and a liquid extract of plantain leaf in ethanol/water manufactured by Herbs Etc (Santa Fe, New Mexico) purchased from a herbal store in Houston, TX were used in this study. A dry plantain leaf used for making plantain tea was also obtained. These are the three most commonly available preparations in Houston, as determined by calling several herbal stores. The dry leaf was extracted with either methanol or ethanol:water (60:40 by volume). The dry content of capsule was also extracted with either methanol or ethanol:water (100 mg dry powder/ mL of solvent). The liquid plantain extract available commercially was used as supplied.We chose methanol as a solvent for extraction because of the solubility of digoxin and other cardiac glycosides in this solvent. In addition, we used ethanol:water as an alternative solvent because the liquid plantain product was an ethanol:water extract of dry plantain leaf.
Aliquots of drug-free serum were supplemented with the three di¡erent plantain products (dry leaf, capsule and liquid extract of leaf) to achieve a ¢nal concentration of 100 mL of extract per mL of serum. This corresponds to an extremely high in vitro concentration of plantain compared with expected in vivo concentrations after consumption of plantain using the recommended dose. However, we investigated a worst possible scenario. For supplementation with various plantain extracts, we added microlitre quantities of liquid extract in a dry test tube, evaporated the organic phase almost to dryness at room temperature using nitrogen and then reconstituted the dry residue with drug-free serum. This step was performed to eliminate potential matrix e¡ects. In order to further ensure that supplementation of drugfree serum with organic extract did not have any e¡ect on measurement of drug concentrations using immunoassays, we added 100 mL of methanol or ethanol:water (60:40 by volume), evaporated the liquid almost to dryness and then reconstituted the residue with 1mL of drug-free serum and analysed the serum for any apparent drug concentration. The apparent digoxin concentration was measured by both £uorescence polarization immunoassay (FPIA) and microparticle enzyme immunoassay (MEIA). Concentrations of tobramycin, procainamide, tricyclic antidepressants (TCA), quinidine and carbamazepine were measured using appropriate immunoassays on an AxSYM analyser (Abbott Laboratories, Abbott Park, IL). Concentrations of phenytoin, theophylline, valproic acid, amikacin, gentamycin, phenobarbital, salicylate and acetaminophen (paracetamol) were measured using the Hitachi P 800 modular system and assay kits available from Roche Diagnostics (Indianapolis, IN) . Because cross-reactivity should be tested in the presence of the primary analyte, 4 we also supplemented aliquots of one digoxin pool with plantain extract (100 mL of extract per mL of serum) and then measured digoxin concentrations by using both FPIA and MEIA.
In a separate experiment, plantain extracts of dry capsule contents, plantain leaf and liquid plantain extract were analysed by thin layer chromatography (TLC) for the presence of cardiac glycosides, using the reverse-phase TLC method as described by Ikeda et al. 5 for quantitative determination of cardiac glycosides in D. lantana leaves. We used commercially available digoxin and digitoxin standards for comparison.
Results and discussion
We observed no apparent concentration of digoxin or any other drug when blank methanol or ethanol:water was reconstituted with drug-free serum after evaporating the organic phase almost to dryness. We also observed no apparent digoxin concentration when aliquots of drug-free serum were supplemented with various plantain products. Moreover, when aliquots of digoxin pool were further supplemented with various plantain extracts, the observed digoxin concentrations compared well with the original digoxin concentration in serum. For example, original digoxin concentration in the pool as measured by FPIA was 1.05 ng/mL. In the presence of 100 mL of plantain extract (commercially available plantain extract, Herbs Etc), the observed digoxin value was 1.03 ng/mL. We observed similar results with other plantain products tested as well as with the MEIA assay (Table 1) . We did not observe the presence of either digoxin or digitoxin by TLC analysis. Moreover, when aliquots of drug-free serum pools supplemented with various plantain products were tested for any cross-reactivity with immunoassay of13 other commonly monitored therapeutic drugs, we observed values less than the sensitivity limit of the respective assay, indicating that it is unlikely that plantain interferes with monitoring of these drugs.
We used FPIA assay to investigate the potential interference of plantain with digoxin because this assay is based on a polyclonal rabbit antibody against digoxin and known to cross-react with variety of Chinese medicines containing various active ingredients with structural similarity with digoxin. Other monoclonalbased digoxin immunoassays showed lower crossreactivity with various Chinese medicines 6 or plant poisons such as oleander, where the active ingredient, oleandrin, has structural similarity with digoxin. Our results clearly indicate that the three commercially available plantain products we studied did not interfere with therapeutic drug monitoring of digoxin using FPIA or MEIA or with the therapeutic drug monitoring of thirteen other commonly monitored drugs using immunoassay. Moreover, no digoxin or digitoxin was detected in plantain products by TLC. Combined with lack of cross-reactivity with FPIA assay, we conclude that the plantain products studied were not contaminated with digitalis, as earlier reports indicated. Therefore, previous reports of contamination of plantain products with digitalis may be isolated incidents and not a general problem of plantain products. An alternative possibility is that after publication of these reports on serious problem of contamination of plantain with D. Lantana, manufacturers improved the quality of their plantain products so that the three products we studied are no longer contaminated with digitalis. 
